BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-72. [PMID: 29520964 DOI: 10.1002/ejhf.1170] [Cited by in Crossref: 234] [Cited by in F6Publishing: 181] [Article Influence: 58.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang W, Lee SGS, How CH. Management of the heart failure patient in the primary care setting. Singapore Med J 2020;61:225-9. [PMID: 32754766 DOI: 10.11622/smedj.2020073] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Longo M, Scappaticcio L, Cirillo P, Maio A, Carotenuto R, Maiorino MI, Bellastella G, Esposito K. Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues. Biomolecules 2022;12:272. [DOI: 10.3390/biom12020272] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rørth R, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, Bruun NE, Eiskjær H, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Køber L, Kristensen SL. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace 2019;21:1203-10. [PMID: 31323662 DOI: 10.1093/europace/euz114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019;21:665-75. [PMID: 30895697 DOI: 10.1002/ejhf.1432] [Cited by in Crossref: 110] [Cited by in F6Publishing: 87] [Article Influence: 36.7] [Reference Citation Analysis]
5 Cai X, Zhu Q, Wu T, Zhu B, Aierken X, Ahmat A, Li N. Development and Validation of a Novel Model for Predicting the 5-Year Risk of Type 2 Diabetes in Patients with Hypertension: A Retrospective Cohort Study. Biomed Res Int 2020;2020:9108216. [PMID: 33029529 DOI: 10.1155/2020/9108216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JG, Coats AJ, Crespo-leiro MG, Farmakis D, Gilard M, Heyman S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CS, Lyon AR, Mcmurray JJ, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GM, Ruschitzka F, Skibelund AK. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Monteiro P, Aguiar C, Matos P, Silva-nunes J, Birne R, Branco P, Calado J, Melo M, Polónia J. Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. Revista Portuguesa de Cardiologia (English Edition) 2019;38:721-35. [DOI: 10.1016/j.repce.2019.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail 2019;6:1105-27. [PMID: 31997538 DOI: 10.1002/ehf2.12555] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
9 Tougaard RS, Jorsal A, Tarnow L, Hansson NH, Kistorp C, Schou M, Nielsen R, Flyvbjerg A, Videbaek L, Mølgaard H, Nielsen JC, Gustafsson I, Wiggers H. Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scand Cardiovasc J 2020;54:294-9. [PMID: 32292074 DOI: 10.1080/14017431.2020.1751873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
10 Ahmad I, Hoda M. Molecular mechanisms of action of resveratrol in modulation of diabetic and non-diabetic cardiomyopathy. Pharmacol Res 2020;161:105112. [PMID: 32758636 DOI: 10.1016/j.phrs.2020.105112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Wang SV, Maro JC, Gagne JJ, Patorno E, Kattinakere S, Stojanovic D, Eworuke E, Baro E, Ouellet-Hellstrom R, Nguyen M, Ma Y, Dashevsky I, Cole D, DeLuccia S, Hansbury A, Pestine E, Kulldorff M. A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics. Am J Epidemiol 2021;190:1424-33. [PMID: 33615330 DOI: 10.1093/aje/kwab034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Li S, Zheng Z, Tang X, Zhong J, Liu X, Zhao Y, Chen L, Zhu J, Liu J, Chen Y. Impact of HbA1c variability on subclinical left ventricular remodeling and dysfunction in patients with type 2 diabetes mellitus. Clin Chim Acta 2020;502:159-66. [PMID: 31866332 DOI: 10.1016/j.cca.2019.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117. [PMID: 30132036 DOI: 10.1007/s00125-018-4670-7] [Cited by in Crossref: 308] [Cited by in F6Publishing: 258] [Article Influence: 77.0] [Reference Citation Analysis]
14 Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499. [PMID: 34859070 DOI: 10.3389/fcvm.2021.754499] [Reference Citation Analysis]
15 Rieth AJ, Hamm CW, Wanner C, Mitrovic V, Keller T. [Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review]. Herz 2021;46:151-8. [PMID: 33044563 DOI: 10.1007/s00059-020-04994-0] [Reference Citation Analysis]
16 Manolis AA, Manolis TA, Manolis AS. Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”. Drugs 2018;78:1567-92. [DOI: 10.1007/s40265-018-0985-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Bowes CD, Lien LF, Butler J. Clinical aspects of heart failure in individuals with diabetes. Diabetologia 2019;62:1529-38. [PMID: 31342083 DOI: 10.1007/s00125-019-4958-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
18 Tsvetkov VA, Krutikov ES, Chistyakova SI. [Subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus]. Probl Endokrinol (Mosk) 2020;66:56-63. [PMID: 33351313 DOI: 10.14341/probl12359] [Reference Citation Analysis]
19 Angelini G, Albanese M, Ursi R, Lisi F, Bellino MC, Amato L, Gioia MI, Parisi G, Brunetti ND, Piazzolla G, Ciccone MM, Iacoviello M. Eligibility of outpatients with chronic heart failure for sodium-glucose co-transporter-2 inhibitors. ESC Heart Fail 2021;8:2951-8. [PMID: 33991178 DOI: 10.1002/ehf2.13380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Staszewsky L, Baviera M, Tettamanti M, Colacioppo P, Robusto F, D'Ettorre A, Lepore V, Fortino I, Bisceglia L, Attolini E, Graps EA, Caldo G, Roncaglioni MC, Garattini S, Latini R. Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. BMJ Open Diabetes Res Care 2022;10:e002708. [PMID: 35351688 DOI: 10.1136/bmjdrc-2021-002708] [Reference Citation Analysis]
21 Pérez-belmonte LM, Sanz-cánovas J, García de Lucas MD, Ricci M, Avilés-bueno B, Cobos-palacios L, Pérez-velasco MA, López-sampalo A, Bernal-lópez MR, Jansen-chaparro S, Miramontes-gonzález JP, Gómez-huelgas R. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Front Endocrinol 2022;13:851035. [DOI: 10.3389/fendo.2022.851035] [Reference Citation Analysis]
22 Lalic NM. Interdisciplinary assessment and diagnostic algorithm: The role of the diabetologist. Diabetes Res Clin Pract 2021;176:108850. [PMID: 33957141 DOI: 10.1016/j.diabres.2021.108850] [Reference Citation Analysis]
23 Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:391-412. [PMID: 32133741 DOI: 10.1002/ejhf.1741] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 28.0] [Reference Citation Analysis]
24 Meindl C, Hochadel M, Frankenstein L, Bruder O, Pauschinger M, Hambrecht R, von Scheidt W, Pfister O, Hartmann A, Maier LS, Senges J, Unsöld B. The role of diabetes in cardiomyopathies of different etiologies-Characteristics and 1-year follow-up results of the EVITA-HF registry. PLoS One 2020;15:e0234260. [PMID: 32525964 DOI: 10.1371/journal.pone.0234260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Cerqueiro-gonzález J, González-franco Á, Carrascosa-garcía S, Soler-rangel L, Ruiz-laiglesia F, Epelde-gonzalo F, Dávila-ramos M, Casado-cerrada J, Casariego-vales E, Manzano L. Benefits of a comprehensive care model in patients with heart failure and preserved ejection fraction: The UMIPIC program. Revista Clínica Española (English Edition) 2022. [DOI: 10.1016/j.rceng.2021.11.006] [Reference Citation Analysis]
26 Valensi P, Picard S, Pathak A. Type 2 diabetes: Why should diabetologists and cardiologists work more closely together? Diabetes & Metabolism 2019;45:501-4. [DOI: 10.1016/j.diabet.2019.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Formiga F, Camafort M, Carrasco Sánchez FJ. Heart failure and diabetes: The confrontation of two major epidemics of the 21st century. Rev Clin Esp (Barc) 2020;220:135-8. [PMID: 30878139 DOI: 10.1016/j.rce.2019.01.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 DeVore AD, Green JB. Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect? JACC Heart Fail 2018;6:831-2. [PMID: 30196074 DOI: 10.1016/j.jchf.2018.07.014] [Reference Citation Analysis]
29 Sun Y, Si J, Li J, Dai M, King E, Zhang X, Zhang Y, Xia Y, Tse G, Liu Y. Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2021;8:656536. [PMID: 34778384 DOI: 10.3389/fcvm.2021.656536] [Reference Citation Analysis]
30 Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res 2020;126:1501-25. [PMID: 32437308 DOI: 10.1161/CIRCRESAHA.120.315913] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 22.5] [Reference Citation Analysis]
31 Sharma A, Butler J, Zieroth S, Giannetti N, Verma S. Treatment of heart failure with sodium glucose co‐transporter‐2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions. Diabet Med 2019;36:1550-61. [DOI: 10.1111/dme.14140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Dziubak A, Wójcicka G, Wojtak A, Bełtowski J. Metabolic Effects of Metformin in the Failing Heart. Int J Mol Sci 2018;19:E2869. [PMID: 30248910 DOI: 10.3390/ijms19102869] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
33 Dimitriadis K, Tsioufis C, Tousoulis D. Do we need biomarkers for diabetics progressing to heart failure? Hellenic J Cardiol 2018;59:98-9. [PMID: 29940223 DOI: 10.1016/j.hjc.2018.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev 2022. [PMID: 35522391 DOI: 10.1007/s10741-022-10238-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Mordi IR, Lumbers RT, Palmer CNA, Pearson ER, Sattar N, Holmes MV, Lang CC; HERMES Consortium. Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study. Diabetes Care 2021:dc202518. [PMID: 34088700 DOI: 10.2337/dc20-2518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
36 Connelly KA, Sarak B. Diabetes and Myocardial Fibrosis: Is CMR the Force Leading to the Rise of "Scar Wars"? JACC Cardiovasc Imaging 2022;15:809-11. [PMID: 35512953 DOI: 10.1016/j.jcmg.2022.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62:1550-1560. [PMID: 31317230 DOI: 10.1007/s00125-019-4926-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 18.7] [Reference Citation Analysis]
38 Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297-317. [PMID: 31504452 DOI: 10.1093/eurheartj/ehz641] [Cited by in Crossref: 268] [Cited by in F6Publishing: 199] [Article Influence: 134.0] [Reference Citation Analysis]
39 Tromp J, Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, Gomez KA, Dickstein K, Anker SD, Metra M, Lang CC, Ng LL, van der Harst P, van Veldhuisen DJ, van der Meer P, Lam CSP, Zannad F, Sama IE. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. JACC Heart Fail 2020;8:234-42. [PMID: 32035890 DOI: 10.1016/j.jchf.2019.11.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
40 Farmakis D, Butler J, Filippatos G. Sodium-glucose co-transporter 2 inhibitors: 'a tale of two sisters', diabetes and heart failure. Eur J Heart Fail 2020;22:1259-62. [PMID: 32533724 DOI: 10.1002/ejhf.1935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Vaccaro O, Riccardi G, Maggioni AP. Risk of heart failure in diabetic patients receiving sulfonylureas: Risk of heart failure in diabetic patients receiving sulfonylureas. Eur J Heart Fail 2018;20:1371-2. [DOI: 10.1002/ejhf.1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Jung CH, Mok JO. Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab (Seoul) 2020;35:260-71. [PMID: 32615710 DOI: 10.3803/EnM.2020.35.2.260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Sohrabi C, Saberwal B, Lim WY, Tousoulis D, Ahsan S, Papageorgiou N. Heart Failure in Diabetes Mellitus: An Updated Review. Curr Pharm Des 2020;26:5933-52. [PMID: 33213313 DOI: 10.2174/1381612826666201118091659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab 2020;22:1607-18. [PMID: 32363737 DOI: 10.1111/dom.14074] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
45 Kruik-Kollöffel WJ, Vallejo-Yagüe E, Movig KLL, Linssen GCM, Heintjes EM, van der Palen J. Non-cardiovascular medication and readmission for heart failure: an observational cohort study. Int J Clin Pharm 2022. [PMID: 35633434 DOI: 10.1007/s11096-022-01418-3] [Reference Citation Analysis]
46 Kalliora C, Kyriazis ID, Oka SI, Lieu MJ, Yue Y, Area-Gomez E, Pol CJ, Tian Y, Mizushima W, Chin A, Scerbo D, Schulze PC, Civelek M, Sadoshima J, Madesh M, Goldberg IJ, Drosatos K. Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction. JCI Insight 2019;5:129556. [PMID: 31393858 DOI: 10.1172/jci.insight.129556] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
47 Ye H, He Y, Zheng C, Wang F, Yang M, Lin J, Xu R, Zhang D. Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway. Front Pharmacol 2022;13:816588. [PMID: 35308248 DOI: 10.3389/fphar.2022.816588] [Reference Citation Analysis]
48 Mordi IR, Tee A, Palmer CN, McCrimmon RJ, Doney ASF, Lang CC. Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. ESC Heart Fail 2020;7:1168-77. [PMID: 32239805 DOI: 10.1002/ehf2.12669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
49 Sharma A, Ezekowitz JA. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. Can J Diabetes 2020;44:103-10. [PMID: 31630988 DOI: 10.1016/j.jcjd.2019.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
50 Dzhioeva O, Belyavskiy E. Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. Ther Clin Risk Manag 2020;16:769-85. [PMID: 32904123 DOI: 10.2147/TCRM.S207117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Negahban Z, Rezaei M, Daei MM, Mirzadeh M. Evaluation of the Systolic and Diastolic Right Ventricular Function: A Comparison Between Diabetes, Prediabetes and Normal Patients Without Coronary Artery Disease. Curr Probl Cardiol 2021;46:100817. [PMID: 33765491 DOI: 10.1016/j.cpcardiol.2021.100817] [Reference Citation Analysis]
52 Li Z, Zhao H, Wang J. Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities. Front Cardiovasc Med 2021;8:650278. [PMID: 34026868 DOI: 10.3389/fcvm.2021.650278] [Reference Citation Analysis]
53 Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323. [PMID: 31497854 DOI: 10.1093/eurheartj/ehz486] [Cited by in Crossref: 925] [Cited by in F6Publishing: 738] [Article Influence: 925.0] [Reference Citation Analysis]
54 Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF. Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 1339-81. [DOI: 10.1002/cphy.c180013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
55 Gur FM, Aktas I. The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy. Tissue Cell 2021;71:101582. [PMID: 34171519 DOI: 10.1016/j.tice.2021.101582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Wang L, Cai Y, Jian L, Cheung CW, Zhang L, Xia Z. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy. Cardiovasc Diabetol 2021;20:2. [PMID: 33397369 DOI: 10.1186/s12933-020-01188-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
57 Grigorescu ED, Lacatusu CM, Floria M, Mihai BM, Cretu I, Sorodoc L. Left Ventricular Diastolic Dysfunction in Type 2 Diabetes-Progress and Perspectives. Diagnostics (Basel) 2019;9:E121. [PMID: 31533216 DOI: 10.3390/diagnostics9030121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
58 Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Research and Clinical Practice 2018;143:88-100. [DOI: 10.1016/j.diabres.2018.06.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
59 Segar MW, Khan MS, Patel KV, Vaduganathan M, Kannan V, Willett D, Peterson E, Tang WHW, Butler J, Everett BM, Fonarow GC, Wang TJ, McGuire DK, Pandey A. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. Eur J Heart Fail 2021. [PMID: 34730265 DOI: 10.1002/ejhf.2375] [Reference Citation Analysis]
60 Lim LL, Lau ESH, Fung E, Lee HM, Ma RCW, Tam CHT, Wong WKK, Ng ACW, Chow E, Luk AOY, Jenkins A, Chan JCN, Kong APS. Circulating branched-chain amino acids and incident heart failure in type 2 diabetes: The Hong Kong Diabetes Register. Diabetes Metab Res Rev. 2020;36:e3253. [PMID: 31957226 DOI: 10.1002/dmrr.3253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
61 Armentaro G, D’arrigo G, Miceli S, Cassano V, Perticone M, Maio R, Marra AM, Arturi F, Cittadini A, Tripepi G, Sesti G, Sciacqua A. Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study. Front Physiol 2022;13:897109. [DOI: 10.3389/fphys.2022.897109] [Reference Citation Analysis]
62 Giugliano D, Meier JJ, Esposito K. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes Obes Metab. 2019;21:1081-1087. [PMID: 30609236 DOI: 10.1111/dom.13629] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
63 Savarese G, Vedin O, D'amario D, Uijl A, Dahlström U, Rosano G, Lam CS, Lund LH. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. JACC: Heart Failure 2019;7:306-17. [DOI: 10.1016/j.jchf.2018.11.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
64 Verma S, Sharma A, Kanumilli N, Butler J. Predictors of heart failure development in type 2 diabetes: a practical approach. Curr Opin Cardiol 2019;34:578-83. [PMID: 31219877 DOI: 10.1097/HCO.0000000000000647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
65 Milajerdi A, Djafarian K, Shab-Bidar S, Speakman JR. Pre- and post-diagnosis body mass index and heart failure mortality: a dose-response meta-analysis of observational studies reveals greater risk of being underweight than being overweight. Obes Rev 2018;20:252-61. [PMID: 30565843 DOI: 10.1111/obr.12777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
66 Muñoz-Rivas N, Jiménez-García R, Méndez-Bailón M, Hernández-Barrera V, de Miguel-Díez J, Lorenzo-Villalba N, de Miguel-Yanes JM, López-de-Andrés A. Type 2 diabetes increases the risk of hospital admission for heart failure and reduces the risk of in hospital mortality in Spain (2001-2015). Eur J Intern Med 2019;59:53-9. [PMID: 30143395 DOI: 10.1016/j.ejim.2018.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
67 Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA. The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. Int J Mol Sci 2019;20:E904. [PMID: 30791450 DOI: 10.3390/ijms20040904] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 15.3] [Reference Citation Analysis]
68 Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab 2021;23:75-85. [PMID: 32893440 DOI: 10.1111/dom.14189] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
69 Shang Y, Zhang X, Leng W, Lei X, Chen L, Zhou X, Chow K, Shi Y, Dong J, Liang Z, Wang J. Increased fractal dimension of left ventricular trabeculations is associated with subclinical diastolic dysfunction in patients with type-2 diabetes mellitus. Int J Cardiovasc Imaging 2019;35:665-73. [PMID: 30430327 DOI: 10.1007/s10554-018-1492-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
70 Malik A, Garland E, Drozd M, Palin V, Giannoudi M, Straw S, Jex N, Walker AM, Gierula J, Paton M, Witte KK, Kearney MT, Levelt E, Cubbon RM. Diabetes mellitus and the causes of hospitalisation in people with heart failure. Diab Vasc Dis Res 2022;19:14791641211073943. [PMID: 35236158 DOI: 10.1177/14791641211073943] [Reference Citation Analysis]
71 Guan YZ, Yin RX, Deng GX, Zheng PF, Liu CX, Wei BL. Potential Molecular Mechanism of the NPPB Gene in Postischemic Heart Failure with and without T2DM. Biomed Res Int 2020;2020:2159460. [PMID: 32802835 DOI: 10.1155/2020/2159460] [Reference Citation Analysis]
72 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; Authors/Task Force Members:., ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. [PMID: 35083827 DOI: 10.1002/ejhf.2333] [Cited by in Crossref: 124] [Cited by in F6Publishing: 33] [Article Influence: 124.0] [Reference Citation Analysis]
73 Coats AJ. Heart Failure Association position papers – a new way to advance the field. Eur J Heart Fail 2020;22:6-7. [DOI: 10.1002/ejhf.1704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Tereshchenko SN, Zhirov IV, Uskach TM, Saidova MA, Golitsyn SP, Gupalo EM, Nasonova SN, Narusov OY, Safiullina AA, Tereshchenko AS, Stukalova OV. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Evrazijskij kardiologičeskij žurnal 2020. [DOI: 10.38109/2225-1685-2020-3-6-76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Cavallari I, Maddaloni E, Pieralice S, Mulè MT, Buzzetti R, Ussia GP, Pozzilli P, Grigioni F. The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. J Clin Endocrinol Metab 2020;105:dgaa427. [PMID: 32615596 DOI: 10.1210/clinem/dgaa427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
76 Giugliano D, Maiorino MI, Longo M, Bellastella G, Chiodini P, Esposito K. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine 2019;65:15-24. [DOI: 10.1007/s12020-019-01931-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
77 Godoy LC, Rao V, Farkouh ME. Diabetes and multivessel disease: coronary artery bypass grafting remains king. Current Opinion in Cardiology 2018;33:551-7. [DOI: 10.1097/hco.0000000000000550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Kalliora C, Drosatos K. The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation. J Cardiovasc Pharmacol 2020;76:514-26. [PMID: 33165133 DOI: 10.1097/FJC.0000000000000891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
79 Dutka M, Bobiński R, Ulman-Włodarz I, Hajduga M, Bujok J, Pająk C, Ćwiertnia M. Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Fail Rev 2021;26:603-22. [PMID: 33150520 DOI: 10.1007/s10741-020-10041-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Hirose K, Nakanishi K, Daimon M, Sawada N, Yoshida Y, Iwama K, Yamamoto Y, Ishiwata J, Hirokawa M, Koyama K, Nakao T, Morita H, Di Tullio MR, Homma S, Komuro I. Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese japanese subjects in a general community. Cardiovasc Diabetol 2021;20:22. [PMID: 33478525 DOI: 10.1186/s12933-020-01201-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol 2018;114:2. [PMID: 30443826 DOI: 10.1007/s00395-018-0711-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 17.3] [Reference Citation Analysis]
82 Salvatore T, Pafundi PC, Galiero R, Albanese G, Di Martino A, Caturano A, Vetrano E, Rinaldi L, Sasso FC. The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms. Front Med (Lausanne) 2021;8:695792. [PMID: 34277669 DOI: 10.3389/fmed.2021.695792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sourdon J, Facchin C, Certain A, Viel T, Robin B, Lager F, Marchiol C, Balvay D, Yoganathan T, Favier J, Tharaux PL, Dhaun N, Renault G, Tavitian B. Sunitinib-induced cardiac hypertrophy and the endothelin axis. Theranostics 2021;11:3830-8. [PMID: 33664864 DOI: 10.7150/thno.49837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
84 Farahani-Zangaraki M, Taheri A, Etebari M. Niosome-carvedilol protects DNA damage of supraphysiologic concentrations of insulin using comet assay: An in vitro study. Hum Exp Toxicol 2021;:9603271211036124. [PMID: 34334013 DOI: 10.1177/09603271211036124] [Reference Citation Analysis]
85 Wood N, Straw S, Scalabrin M, Roberts LD, Witte KK, Bowen TS. Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence. ESC Heart Fail 2021;8:3-15. [PMID: 33225593 DOI: 10.1002/ehf2.13121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Zoppini G, Bergamini C, Mantovani A, Dauriz M, Targher G, Rossi A, Bonora E. The E/e' ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. PLoS One 2018;13:e0209794. [PMID: 30589892 DOI: 10.1371/journal.pone.0209794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
87 Sorimachi H, Omote K, Borlaug BA. Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction. Heart Fail Clin 2021;17:483-98. [PMID: 34051978 DOI: 10.1016/j.hfc.2021.02.009] [Reference Citation Analysis]
88 Braha A, Timar B, Diaconu L, Lupusoru R, Vasiluta L, Sima A, Vlad A, Munteanu M, Albai A, Cipu D, Timar R. Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors. Diabetes Metab Syndr Obes 2019;12:2559-66. [PMID: 31824184 DOI: 10.2147/DMSO.S223629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
89 Garnham JO, Roberts LD, Espino-Gonzalez E, Whitehead A, Swoboda PP, Koshy A, Gierula J, Paton MF, Cubbon RM, Kearney MT, Egginton S, Bowen TS, Witte KK. Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology. J Cachexia Sarcopenia Muscle 2020;11:394-404. [PMID: 31863644 DOI: 10.1002/jcsm.12515] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
90 Lainscak M, Omersa D, Sedlar N, Anker SD, Farkas J. Heart failure prevalence in the general population: SOBOTA-HF study rationale and design. ESC Heart Fail 2019;6:1077-84. [PMID: 31347289 DOI: 10.1002/ehf2.12496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
91 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. [PMID: 34447992 DOI: 10.1093/eurheartj/ehab368] [Cited by in Crossref: 209] [Cited by in F6Publishing: 73] [Article Influence: 209.0] [Reference Citation Analysis]
92 Tate M, Prakoso D, Willis AM, Peng C, Deo M, Qin CX, Walsh JL, Nash DM, Cohen CD, Rofe AK, Sharma A, Kiriazis H, Donner DG, De Haan JB, Watson AMD, De Blasio MJ, Ritchie RH. Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. Front Physiol 2019;10:1395. [PMID: 31798462 DOI: 10.3389/fphys.2019.01395] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
93 Liu S, Zhang R, Shang X, Li W. Analysis for warning factors of type 2 diabetes mellitus complications with Markov blanket based on a Bayesian network model. Comput Methods Programs Biomed 2020;188:105302. [PMID: 31923820 DOI: 10.1016/j.cmpb.2019.105302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
94 Tremamunno S, De Vita A, Villano A, Melita V, Ingrasciotta G, Ruscio E, Filice M, Bisignani A, Ravenna SE, Tartaglione L, Rizzo GE, Di Leo M, Felici T, Pitocco D, Lanza GA. Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2021;:e3484. [PMID: 34240534 DOI: 10.1002/dmrr.3484] [Reference Citation Analysis]
95 Jensen J, Schou M, Kistorp C, Faber J, Hansen TW, Jensen MT, Andersen HU, Rossing P, Vilsbøll T, Jørgensen PG. MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. Cardiovasc Diabetol 2020;19:180. [PMID: 33066783 DOI: 10.1186/s12933-020-01155-9] [Reference Citation Analysis]
96 Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, Fernando K, James J, Milne N, Viljoen A, Wilding J; As part of The Improving Diabetes Steering Committee. SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. Diabetes Ther 2019;10:1595-622. [PMID: 31290126 DOI: 10.1007/s13300-019-0657-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
97 Pofi R, Giannetta E, Feola T, Galea N, Barbagallo F, Campolo F, Badagliacca R, Barbano B, Ciolina F, Defeudis G, Filardi T, Sesti F, Minnetti M, Vizza CD, Pasqualetti P, Caboni P, Carbone I, Francone M, Catalano C, Pozzilli P, Lenzi A, Venneri MA, Gianfrilli D, Isidori AM. Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci Transl Med 2022;14:eabl8503. [PMID: 35704597 DOI: 10.1126/scitranslmed.abl8503] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Riess ML, Elorbany R, Weihrauch D, Stowe DF, Camara AKS. PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts. Cells 2020;9:E252. [PMID: 31968546 DOI: 10.3390/cells9010252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
99 Abdelaaty T, Morsy E, Rizq M, Shokry A, Abdelhameid A, Fathalla R. Relation of serum heart type fatty acid binding protein to left ventricular diastolic dysfunction in patients with type 2 diabetes and early diabetic kidney disease. Journal of Diabetes and its Complications 2022. [DOI: 10.1016/j.jdiacomp.2021.108122] [Reference Citation Analysis]
100 Soh JGS, Wong WP, Mukhopadhyay A, Quek SC, Tai BC. Predictors of 30-day unplanned hospital readmission among adult patients with diabetes mellitus: a systematic review with meta-analysis. BMJ Open Diabetes Res Care 2020;8:e001227. [PMID: 32784248 DOI: 10.1136/bmjdrc-2020-001227] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
101 Hupfeld C, Mudaliar S. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits. Diabetes Obes Metab 2019;21:1780-9. [PMID: 30957945 DOI: 10.1111/dom.13740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
102 Cattadori G, Pantanetti P, Ambrosio G. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Research and Clinical Practice 2019;157:107835. [DOI: 10.1016/j.diabres.2019.107835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
103 Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556-77. [PMID: 32855502 DOI: 10.1038/s41574-020-0392-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 40.0] [Reference Citation Analysis]
104 Wang H, Zhang J, Shi CF, Jia J, Zhang ZM, Sun JJ, Lu BB. Distribution of traditional Chinese medicine syndromes in type 2 diabetes mellitus with chronic heart failure: A clinical study. Medicine (Baltimore) 2020;99:e21091. [PMID: 32791683 DOI: 10.1097/MD.0000000000021091] [Reference Citation Analysis]
105 Faconti L, Mills CE, Govoni V, Gu H, Morant S, Jiang B, Cruickshank JK, Webb AJ. Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial. Br J Clin Pharmacol 2019;85:169-80. [PMID: 30294825 DOI: 10.1111/bcp.13783] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
106 Ye G, Wang S, Peng D. Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol 2021;77:787-95. [PMID: 33843765 DOI: 10.1097/FJC.0000000000001018] [Reference Citation Analysis]
107 Coats AJS. Figures of the Heart Failure Association: Petar M. Seferović, President, 2018-2020. Eur J Heart Fail 2019;21:266-8. [PMID: 30883997 DOI: 10.1002/ejhf.1430] [Reference Citation Analysis]
108 Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C. Empagliflozin improves kidney outcomes in patients with or without heart failure. Circ Heart Fail. 2019;12:e005875. [PMID: 31163986 DOI: 10.1161/circheartfailure.118.005875] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
109 Monteiro P, Aguiar C, Matos P, Silva-Nunes J, Birne R, Branco P, Calado J, Melo M, Polónia J. Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. Rev Port Cardiol (Engl Ed) 2019;38:721-35. [PMID: 31892455 DOI: 10.1016/j.repc.2019.02.008] [Reference Citation Analysis]
110 Senni M, Iorio A, Seferović P. Heart failure with preserved ejection fraction in Asia: the far side of the moon? Eur J Heart Fail 2019;21:37-9. [PMID: 30468292 DOI: 10.1002/ejhf.1335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
111 Ohkuma T, Peters SAE, Jun M, Harrap S, Cooper M, Hamet P, Poulter N, Chalmers J, Woodward M; ADVANCE Collaborative Group. Sex-specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: The ADVANCE-ON study. Diabetes Obes Metab 2020;22:1818-26. [PMID: 32476250 DOI: 10.1111/dom.14103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail 2020;22:196-213. [PMID: 31816162 DOI: 10.1002/ejhf.1673] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 21.3] [Reference Citation Analysis]
113 Kleissl-muir S, Rasmussen B, Owen A, Zinn C, Driscoll A. Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis. Front Nutr 2022;9:865489. [DOI: 10.3389/fnut.2022.865489] [Reference Citation Analysis]
114 Fairman E, Delfino F, Mauro V, Charask A, Castillo Costa Y, Rafaelli A, Rojo L, Rodríguez Rowain V, Cáceres L, Barrero C. Diabetes as a Predictor of In-Hospital and One-Year Outcomes After Decompensated Heart Failure. Curr Probl Cardiol 2021;46:100579. [PMID: 32376045 DOI: 10.1016/j.cpcardiol.2020.100579] [Reference Citation Analysis]
115 Ishikawa Y, Lewis RD, Laing EM, Anderson AK, Zhang D, Quyyumi AA, Dunbar SB, Trivedi-kapoor R, L. P. Sattler E. Prevalence and Trends of Type 2 Diabetes Mellitus and Prediabetes among Community-Dwelling Heart Failure Patients in the United States. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovasc Diabetol 2019;18:106. [PMID: 31412874 DOI: 10.1186/s12933-019-0910-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
117 Chiang CE, Wang KL, Cheng HM, Sung SH, Chao TF. Second revolution in cardiovascular prevention. J Chin Med Assoc 2020;83:327-36. [PMID: 32101893 DOI: 10.1097/JCMA.0000000000000276] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Verma S, Mcmurray JJ. The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights From DECLARE-TIMI 58. Circulation 2019;139:2537-41. [DOI: 10.1161/circulationaha.119.040514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
119 Llano A, Mckay G. The treatment of type 2 diabetes in heart failure. Pract Diab 2018;35:123-6. [DOI: 10.1002/pdi.2178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Razaghizad A, Oulousian E, Randhawa VK, Ferreira JP, Brophy JM, Greene SJ, Guida J, Felker GM, Fudim M, Tsoukas M, Peters TM, Mavrakanas TA, Giannetti N, Ezekowitz J, Sharma A. Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis. JAHA. [DOI: 10.1161/jaha.121.024833] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Liu M, Zhang HJ, Song H, Cheng N, Wu YB, Wang R. Effect of diabetes mellitus on long-term outcomes of surgical revascularization in patients with ischemic heart failure: a propensity score-matching study. Chin Med J (Engl) 2021;134:1146-51. [PMID: 33813506 DOI: 10.1097/CM9.0000000000001421] [Reference Citation Analysis]
122 Tanaka A, Node K. Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment. Diabetol Int 2020;11:252-60. [PMID: 32802706 DOI: 10.1007/s13340-020-00445-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Iwakura K. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments. J Echocardiogr 2019;17:177-86. [DOI: 10.1007/s12574-019-00446-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
124 García-Carro C, Vergara A, Agraz I, Jacobs-Cachá C, Espinel E, Seron D, Soler MJ. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. J Clin Med 2019;8:E864. [PMID: 31212945 DOI: 10.3390/jcm8060864] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
125 Cho DH, Yoo BS. Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. Heart Fail Clin 2021;17:315-26. [PMID: 34051964 DOI: 10.1016/j.hfc.2021.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Pérez-Belmonte LM, Ricci M, Sanz-Cánovas J, Cobos-Palacios L, López-Carmona MD, Ruiz-Moreno MI, Millán-Gómez M, Bernal-López MR, Jansen-Chaparro S, Gómez-Huelgas R. De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. J Clin Med 2021;10:2013. [PMID: 34066707 DOI: 10.3390/jcm10092013] [Reference Citation Analysis]
127 Kumar K, Kheiri B, Simpson TF, Osman M, Rahmouni H. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials. Am J Med 2020;133:e625-30. [PMID: 32389659 DOI: 10.1016/j.amjmed.2020.04.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
128 Geurten RJ, Struijs JN, Elissen AMJ, Bilo HJG, van Tilburg C, Ruwaard D. Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016-2018. Pharmacoecon Open 2021. [PMID: 34862962 DOI: 10.1007/s41669-021-00308-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Natali A, Nesti L, Tricò D, Ferrannini E. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol 2021;20:196. [PMID: 34583699 DOI: 10.1186/s12933-021-01385-5] [Reference Citation Analysis]
130 Das US, Paul A, Banerjee S. SGLT2 inhibitors in heart failure with reduced ejection fraction. Egypt Heart J 2021;73:93. [PMID: 34693498 DOI: 10.1186/s43044-021-00218-w] [Reference Citation Analysis]
131 Fox KAA, Metra M, Morais J, Atar D. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol 2020;17:9-21. [DOI: 10.1038/s41569-019-0233-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
132 . Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). Revista Española de Cardiología 2020;73:404.e1-404.e59. [DOI: 10.1016/j.recesp.2019.11.024] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Mai Z, Li H, Chen G, Chen E, Liu L, Lun Z, Lai W, Zhou C, Yu S, Liu J, Chen S, Chen J, Liu Y. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology. Cardiovasc Drugs Ther 2021. [PMID: 34028657 DOI: 10.1007/s10557-021-07186-y] [Reference Citation Analysis]
134 Chiang CE, Ueng KC, Chao TH, Lin TH, Wu YJ, Wang KL, Sung SH, Yeh HI, Li YH, Liu PY, Chang KC, Shyu KG, Huang JL, Tsai CD, Hung HF, Liu ME, Chao TF, Cheng SM, Cheng HM, Chu PH, Yin WH, Wu YW, Chen WJ, Lai WT, Lin SJ, Yeh SJ, Hwang JJ. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. J Chin Med Assoc 2020;83:587-621. [PMID: 32628427 DOI: 10.1097/JCMA.0000000000000359] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Ahmad E, Sargeant JA, Zaccardi F, Khunti K, Webb DR, Davies MJ. Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes? Pharmaceuticals (Basel) 2020;13:E427. [PMID: 33261058 DOI: 10.3390/ph13120427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Tang Z, Wang P, Dong C, Zhang J, Wang X, Pei H, Yan L. Oxidative Stress Signaling Mediated Pathogenesis of Diabetic Cardiomyopathy. Oxidative Medicine and Cellular Longevity 2022;2022:1-8. [DOI: 10.1155/2022/5913374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
137 Randhawa VK, Dhanvantari S, Connelly KA. How Diabetes and Heart Failure Modulate Each Other and Condition Management. Can J Cardiol 2021;37:595-608. [PMID: 33276047 DOI: 10.1016/j.cjca.2020.11.014] [Reference Citation Analysis]
138 Kubíčková M, Bis J. (Type 2 diabetes and heart failure - how to optimize cooperation of cardiologist and diabetologist). Cor Vasa 2021;63:373-7. [DOI: 10.33678/cor.2021.084] [Reference Citation Analysis]
139 Masip J, Povar-Echeverría M, Peacock WF, Jacob J, Gil V, Herrero P, Llorens P, Alquézar-Arbé A, Sánchez C, Martín-Sánchez FJ, Miró Ò; Researchers of the ICA-SEMES and EAHFE Registry. Impact of diabetes and on-arrival hyperglycemia on short-term outcomes in acute heart failure patients. Intern Emerg Med 2022. [PMID: 35352299 DOI: 10.1007/s11739-022-02965-3] [Reference Citation Analysis]
140 Del Torto A, Guaricci AI, Pomarico F, Guglielmo M, Fusini L, Monitillo F, Santoro D, Vannini M, Rossi A, Muscogiuri G, Baggiano A, Pontone G. Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2022;9:758975. [DOI: 10.3389/fcvm.2022.758975] [Reference Citation Analysis]
141 Hotta VT, Rassi DDC, Pena JLB, Vieira MLC, Rodrigues ACT, Cardoso JN, Ramires FJA, Nastari L, Mady C, Fernandes F. Análise Crítica e Limitações do Diagnóstico de Insuficiência Cardíaca com Fração de Ejeção Preservada (ICFEp). Arquivos Brasileiros de Cardiologia 2022. [DOI: 10.36660/abc.20210052] [Reference Citation Analysis]
142 Miao H, Li X, Zhou C, Liang Y, Li D, Ji Q. NR4A2 alleviates cardiomyocyte loss and myocardial injury in rats by transcriptionally suppressing CCR5 and inducing M2 polarization of macrophages. Microvasc Res 2021;140:104279. [PMID: 34774582 DOI: 10.1016/j.mvr.2021.104279] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Avogaro A, Barillà F, Cavalot F, Consoli A, Federici M, Mancone M, Paolillo S, Pedrinelli R, Perseghin G, Perrone Filardi P, Scicali R, Sinagra G, Spaccarotella C, Indolfi C, Purrello F. Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutr Metab Cardiovasc Dis 2021;31:1671-90. [PMID: 33994263 DOI: 10.1016/j.numecd.2021.02.029] [Reference Citation Analysis]
144 Reifsnider OS, Kansal AR, Franke J, Lee J, George JT, Brueckmann M, Kaspers S, Brand SB, Ustyugova A, Linden S, Stargardter M, Hau N. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC Heart Fail 2020. [PMID: 32909680 DOI: 10.1002/ehf2.12985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
145 Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, O'Meara E, Ahnadi C, White M, Garceau P, Racine N, Parent MC, Liszkowski M, Giraldeau G, Rouleau JL, Ducharme A. Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? JACC Heart Fail 2020;8:725-38. [PMID: 32800509 DOI: 10.1016/j.jchf.2020.04.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
146 Fadini GP, Avogaro A. A simple way to spotlight hidden heart failure in type 2 diabetes? Eur J Heart Fail 2021;23:1094-6. [PMID: 34050581 DOI: 10.1002/ejhf.2258] [Reference Citation Analysis]
147 Winell K, Pietilä A, Salomaa V. Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes - a nation-wide study from Finland in 1996-2012. Ann Med 2019;51:174-81. [PMID: 31055965 DOI: 10.1080/07853890.2019.1602734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Wang Y, Han D, Zhou T, Chen C, Cao H, Zhang JZ, Ma N, Liu C, Song M, Shi J, Jin X, Cao F, Dong N. DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells. Eur Heart J 2021;42:2935-51. [PMID: 34179958 DOI: 10.1093/eurheartj/ehab316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Feng X, Chen W, Ni X, Little PJ, Xu S, Tang L, Weng J. Metformin, Macrophage Dysfunction and Atherosclerosis. Front Immunol 2021;12:682853. [PMID: 34163481 DOI: 10.3389/fimmu.2021.682853] [Reference Citation Analysis]
150 Tromp J, Collins SP. Dapagliflozin in heart failure: new frontiers. Eur J Heart Fail 2019;21:1412-4. [PMID: 31746109 DOI: 10.1002/ejhf.1633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 García-Olmos L, Aguilar R, Lora D, Carmona M, Alberquilla A, García-Caballero R, Sánchez-Gómez L; CHIC Group. Development of a predictive model of hospitalization in primary care patients with heart failure. PLoS One 2019;14:e0221434. [PMID: 31419267 DOI: 10.1371/journal.pone.0221434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
152 León Jiménez D, Gómez Huelgas R, Fernández Romero AJ, López Chozas JM, Pérez de Isla L, Miramontes González JP. Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors. Rev Clin Esp (Barc) 2019;219:208-17. [PMID: 30553441 DOI: 10.1016/j.rce.2018.09.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Lee WS, Kim J. Application of Animal Models in Diabetic Cardiomyopathy. Diabetes Metab J 2021;45:129-45. [PMID: 33813812 DOI: 10.4093/dmj.2020.0285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
154 Lambadiari V, Thymis J, Kouretas D, Skaperda Z, Tekos F, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Tsoumani M, Chania C, Katogiannis K, Dimitriadis G, Bamias A, Ikonomidis I. Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes. Antioxidants (Basel) 2021;10:1379. [PMID: 34573011 DOI: 10.3390/antiox10091379] [Reference Citation Analysis]
155 Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2019;21:1338-52. [PMID: 31127678 DOI: 10.1002/ejhf.1492] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
156 Smiseth OA, Morris DA, Cardim N, Cikes M, Delgado V, Donal E, Flachskampf FA, Galderisi M, Gerber BL, Gimelli A, Klein AL, Knuuti J, Lancellotti P, Mascherbauer J, Milicic D, Seferovic P, Solomon S, Edvardsen T, Popescu BA; Reviewers: This document was reviewed by members of the 2018–2020 EACVI Scientific Documents Committee: Philippe B. Bertrand, Marc Dweck, Kristina H. Haugaa, Leyla Elif Sade, Ivan Stankovic; by external reviewers: Jong-Won Ha, Sherif Nagueh, Jae K. Oh, Nobuyuki Ohte; and by the 2020–2022 EACVI President: Bernard Cosyns. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2021:jeab154. [PMID: 34729586 DOI: 10.1093/ehjci/jeab154] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail 2020;22:604-17. [DOI: 10.1002/ejhf.1708] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
158 Saotome M, Ikoma T, Hasan P, Maekawa Y. Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. Int J Mol Sci 2019;20:E3552. [PMID: 31330848 DOI: 10.3390/ijms20143552] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
159 Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation 2021. [PMID: 34775784 DOI: 10.1161/CIRCULATIONAHA.121.057983] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
160 Berliner D, Bauersachs J. New drugs: big changes in conservative heart failure therapy? Eur J Cardiothorac Surg. 2019;55:i3-i10. [PMID: 31106335 DOI: 10.1093/ejcts/ezy421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Zhang BL, Jin X, Sun LH, Guo XD. Needle-shaped glucose sensor based on polypyrrole doped with glucose oxidase. Microchemical Journal 2020;158:105217. [DOI: 10.1016/j.microc.2020.105217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Verma S, Klug E, Mareev VY, Kobalava ZD, Connelly KA, Arici M, Berwanger O, Santoso A, Mehta R, Meglis G, Kosiborod MN. Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Curr Opin Cardiol 2020;35:589-601. [PMID: 32694262 DOI: 10.1097/HCO.0000000000000774] [Reference Citation Analysis]
163 Devarajan A, Karuppiah K, Venkatasalam R, Avasarala S, Subramanian S, Immaneni S, Viswanathan V. Heart failure in people with type 2 diabetes vs. those without diabetes: A retrospective observational study from South India. Diabetes Metab Syndr 2021;15:39-43. [PMID: 33307298 DOI: 10.1016/j.dsx.2020.11.022] [Reference Citation Analysis]
164 Liu B, Wang Y, Zhang Y, Yan B. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Curr Top Med Chem. 2019;19:1818-1849. [PMID: 31456521 DOI: 10.2174/1568026619666190828161409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
165 Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur J Prev Cardiol 2020;27:27-34. [PMID: 33238738 DOI: 10.1177/2047487320960288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
166 Hassanabad MF, Abad ZFH. Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2? Diabetes Metab Syndr 2019;13:1893-6. [PMID: 31235111 DOI: 10.1016/j.dsx.2019.04.041] [Reference Citation Analysis]
167 Gargiulo P, Marsico F, Renga F, Dell'Aversana S, Esposito I, Marciano C, Dellegrottaglie S, Perrone-Filardi P, Paolillo S. The metabolic syndrome in heart failure: insights to specific mechanisms. Heart Fail Rev 2020;25:1-7. [PMID: 31414215 DOI: 10.1007/s10741-019-09838-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
168 McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 2019;21:1402-11. [PMID: 31309699 DOI: 10.1002/ejhf.1548] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 25.0] [Reference Citation Analysis]
169 Braunwald E. Diabetes, heart failure, and renal dysfunction: The vicious circles. Progress in Cardiovascular Diseases 2019;62:298-302. [DOI: 10.1016/j.pcad.2019.07.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 16.3] [Reference Citation Analysis]
170 Yurista SR, Silljé HH, Oberdorf‐maass SU, Schouten E, Pavez Giani MG, Hillebrands J, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD. Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2019;21:862-73. [DOI: 10.1002/ejhf.1473] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 28.3] [Reference Citation Analysis]
171 Zhang Z, Wang J, Zhu Y, Zhang H, Wang H. Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism. Mol Med Rep 2019;20:4612-22. [PMID: 31702040 DOI: 10.3892/mmr.2019.10716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
172 Gamrat A, Surdacki MA, Chyrchel B, Surdacki A. Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis. J Clin Med 2020;9:E2090. [PMID: 32635218 DOI: 10.3390/jcm9072090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
173 Scuteri A. Characteristics that influence the diagnosis and treatment of diabetes in geriatric patients over 75. JGG 2021;69:238-40. [DOI: 10.36150/2499-6564-n448] [Reference Citation Analysis]
174 Ruocco G, Evangelista I, Franci B, Lucani B, Martini S, Nuti R, Palazzuoli A. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome. Journal of Cardiovascular Medicine 2019;20:81-90. [DOI: 10.2459/jcm.0000000000000741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
175 Scheen AJ. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf 2018;17:837-48. [PMID: 30068236 DOI: 10.1080/14740338.2018.1497159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
176 Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci (Lond) 2018;132:1329-39. [PMID: 29954951 DOI: 10.1042/CS20171298] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
177 Tamargo J. Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. Eur Cardiol. 2019;14:23-32. [PMID: 31131034 DOI: 10.15420/ecr.2018.34.2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
178 Chee KH, Tan KL, Luqman I, Saiful SS, Chew YY, Chinna K, Tan ATB. Prevalence and Predictors of Left Ventricular Diastolic Dysfunction in Malaysian Patients With Type 2 Diabetes Mellitus Without Prior Known Cardiovascular Disease. Front Cardiovasc Med 2021;8:676862. [PMID: 34646868 DOI: 10.3389/fcvm.2021.676862] [Reference Citation Analysis]
179 Anker MS, Hadzibegovic S, Lena A, Haverkamp W. The difference in referencing in Web of Science, Scopus, and Google Scholar. ESC Heart Fail 2019;6:1291-312. [PMID: 31886636 DOI: 10.1002/ehf2.12583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
180 Clodi M, Saely CH, Hoppichler F, Resl M, Steinwender C, Stingl H, Wascher TC, Winhofer-Stöckl Y, Sourij H. [Diabetes mellitus, coronary artery disease und heart disease (Update 2019)]. Wien Klin Wochenschr 2019;131:169-73. [PMID: 30980152 DOI: 10.1007/s00508-019-1488-3] [Reference Citation Analysis]
181 Birkenfeld AL, Jordan J, Dworak M, Merkel T, Burnstock G. Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts. Pharmacol Ther 2019;194:132-44. [PMID: 30149104 DOI: 10.1016/j.pharmthera.2018.08.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
182 Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E; D&CVD EASD Study Group. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol 2021;20:218. [PMID: 34740359 DOI: 10.1186/s12933-021-01408-1] [Reference Citation Analysis]
183 Rajbhandari J, Fernandez CJ, Agarwal M, Yeap BXY, Pappachan JM. Diabetic heart disease: A clinical update. World J Diabetes 2021;12:383-406. [PMID: 33889286 DOI: 10.4239/wjd.v12.i4.383] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
184 Rosano GMC, Seferović PM. Physiological monitoring in the complex multi-morbid heart failure patient - Introduction. Eur Heart J Suppl 2019;21:M1-4. [PMID: 31908606 DOI: 10.1093/eurheartj/suz229] [Reference Citation Analysis]
185 Gregers MCT, Schou M, Jensen MT, Jensen J, Petrie MC, Vilsbøll T, Goetze JP, Rossing P, Jørgensen PG. Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. Scandinavian Cardiovascular Journal 2022;56:256-63. [DOI: 10.1080/14017431.2022.2095435] [Reference Citation Analysis]
186 Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetol Metab Syndr 2019;11:80. [PMID: 31572499 DOI: 10.1186/s13098-019-0476-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
187 Liang B, Zhao YX, Zhang XX, Liao HL, Gu N. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol 2020;19:55. [PMID: 32375806 DOI: 10.1186/s12933-020-01024-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
188 Papp Z, Tóth A. New treatment options to reduce heart failure hospitalization. ESC Heart Fail 2020. [PMID: 33271634 DOI: 10.1002/ehf2.13171] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, Møller DV, Zinman B; DEVOTE Study Group. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18:156. [PMID: 31729990 DOI: 10.1186/s12933-019-0960-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Polovina M, Lund LH, Đikić D, Petrović-Đorđević I, Krljanac G, Milinković I, Veljić I, Piepoli MF, Rosano GMC, Ristić AD, Ašanin M, Seferović PM. Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation. Eur J Heart Fail 2020;22:113-25. [PMID: 31822042 DOI: 10.1002/ejhf.1666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
191 Scherbakov N, Doehner W. Comment on 'Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes' by Niedziela et al. J Cachexia Sarcopenia Muscle 2020;11:1867-8. [PMID: 33241893 DOI: 10.1002/jcsm.12649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Ministrini S, Andreozzi F, Montecucco F, Minetti S, Bertolotto M, Liberale L, Mannino GC, Succurro E, Cassano V, Miceli S, Perticone M, Sesti G, Sciacqua A, Carbone F. Neutrophil degranulation biomarkers characterize restrictive echocardiographic pattern with diastolic dysfunction in patients with diabetes. Eur J Clin Invest 2021;:e13640. [PMID: 34129696 DOI: 10.1111/eci.13640] [Reference Citation Analysis]
193 Seferović PM, Seferović JP, Polovina MM. Diving into the unknown: sodium–glucose cotransporter‐2 inhibitors in heart failure without diabetes. Eur J Heart Fail 2019;21:874-6. [DOI: 10.1002/ejhf.1500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
194 Gao C, Ren SV, Yu J, Baal U, Thai D, Lu J, Zeng C, Yan H, Wang Y. Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure. JACC Basic Transl Sci 2019;4:161-72. [PMID: 31061918 DOI: 10.1016/j.jacbts.2018.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
195 McAllister DA, Read SH, Kerssens J, Livingstone S, McGurnaghan S, Jhund P, Petrie J, Sattar N, Fischbacher C, Kristensen SL, McMurray J, Colhoun HM, Wild SH. Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation 2018;138:2774-86. [PMID: 29950404 DOI: 10.1161/CIRCULATIONAHA.118.034986] [Cited by in Crossref: 64] [Cited by in F6Publishing: 26] [Article Influence: 21.3] [Reference Citation Analysis]
196 Marwick TH, Gimelli A, Plein S, Bax JJ, Charron P, Delgado V, Donal E, Lancellotti P, Levelt E, Maurovich-Horvat P, Neubauer S, Pontone G, Saraste A, Cosyns B, Edvardsen T, Popescu BA, Galderisi M, Derumeaux G, Bäck M, Bertrand PB, Dweck M, Keenan N, Magne J, Neglia D, Stankovic I; (Co-Chair)., Reviewers: This document was reviewed by members of the 2020–2022 EACVI Scientific Documents Committee:. Multimodality imaging approach to left ventricular dysfunction in diabetes: an expert consensus document from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2021:jeab220. [PMID: 34739054 DOI: 10.1093/ehjci/jeab220] [Reference Citation Analysis]
197 Martens P, Janssens J, Ramaekers J, Dupont M, Mullens W. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiol 2020;75:211-7. [PMID: 30736724 DOI: 10.1080/00015385.2019.1569313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Lazareva NV, Oshchepkova EV, Orlovsky AA, Tereschenko SN. [Clinical characteristics and quality assessment of the treatment of patients with chronic heart failure with diabetes mellitus]. Ter Arkh 2020;92:37-44. [PMID: 32598696 DOI: 10.26442/00403660.2020.04.000474] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Patoulias D, Papadopoulos C, Doumas M. Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. Eur J Intern Med 2021;87:100-1. [PMID: 33632595 DOI: 10.1016/j.ejim.2021.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology 2021;77:772-810. [DOI: 10.1016/j.jacc.2020.11.022] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 53.0] [Reference Citation Analysis]
201 Alkhezi OS, Alsuhaibani HA, Alhadyab AA, Alfaifi ME, Alomrani B, Aldossary A, Alfayez OM. Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies. Prim Care Diabetes 2021:S1751-9918(21)00049-8. [PMID: 33926837 DOI: 10.1016/j.pcd.2021.04.005] [Reference Citation Analysis]
202 Triposkiadis F, Xanthopoulos A, Bargiota A, Kitai T, Katsiki N, Farmakis D, Skoularigis J, Starling RC, Iliodromitis E. Diabetes Mellitus and Heart Failure. J Clin Med 2021;10:3682. [PMID: 34441977 DOI: 10.3390/jcm10163682] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Wu Q, Liu M, Fang Z, Li C, Zou F, Hu L, Zhang W. Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials. J Clin Pharm Ther 2021. [PMID: 34544199 DOI: 10.1111/jcpt.13521] [Reference Citation Analysis]
204 Hong T, Su Q, Li X, Shan Z, Chen L, Peng Y, Chen L, Yan L, Bao Y, Lyu Z, Shi L, Wang W, Guo L, Ning G, Mu Y, Zhu D. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Diabetes Metab Res Rev 2021;37:e3416. [PMID: 33120435 DOI: 10.1002/dmrr.3416] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Metra M. January 2019 at a glance: prognostic assessment, left ventricular assist devices, disease management and quality of care: January 2019 at a glance: prognostic assessment, left ventricular assist devices, disease management and quality of care. Eur J Heart Fail 2019;21:1-2. [DOI: 10.1002/ejhf.1254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Cunha FM, Pereira J, Marques P, Ribeiro A, Bettencourt P, Lourenço P. Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. J Cardiovasc Med (Hagerstown) 2020;21:21-6. [PMID: 31714331 DOI: 10.2459/JCM.0000000000000896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
207 Rodriguez-ramos MA. Diabetic Cardiomyopathy: Five Major Questions with Simple Answers. US Cardiology Review 2019;13:46-8. [DOI: 10.15420/usc.2018.18.2] [Reference Citation Analysis]
208 Zhou Y, Wang M, Wang S, Li N, Zhang S, Tang S, Shi Q, Zhao Y, Li J, Zeng Y, Song H, Tian H, Li S, Li S. Diabetes in Patients With Heart Failure With Reduced Ejection Fraction During Hospitalization: A Retrospective Observational Study. Front Endocrinol (Lausanne) 2021;12:727188. [PMID: 34456878 DOI: 10.3389/fendo.2021.727188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
209 Perrone Filardi P, Bossone E. Understanding the Pathophysiology to Improve the Therapeutic Management: Focus on Metabolic and Hormonal Comorbidities in Heart Failure. Heart Fail Clin 2019;15:xi-xii. [PMID: 31079701 DOI: 10.1016/j.hfc.2019.04.001] [Reference Citation Analysis]
210 Zhang F, Ji L, Hong T, Guo L, Li Y, Zhu Z, Liu X, Liu F, Tang L, Zhang Y, Li J, Lü Q, Tong N. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J Evid Based Med 2022. [PMID: 35715995 DOI: 10.1111/jebm.12474] [Reference Citation Analysis]
211 Alfuhied A, Gulsin GS, Athithan L, Brady EM, Parke K, Henson J, Redman E, Marsh AM, Yates T, Davies MJ, McCann GP, Singh A. The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study. Int J Cardiovasc Imaging 2022. [PMID: 35233724 DOI: 10.1007/s10554-022-02578-z] [Reference Citation Analysis]
212 Kylies D, Freitag-Wolf S, Fulisch F, Seoudy H, Kuhn C, Kihm LP, Pühler T, Lutter G, Dempfle A, Frey N, Feldkamp T, Frank D. Improvement of renal function after transcatheter aortic valve replacement and its impact on survival. BMC Nephrol 2021;22:77. [PMID: 33653283 DOI: 10.1186/s12882-021-02274-5] [Reference Citation Analysis]
213 Salvatore T, Pafundi PC, Marfella R, Sardu C, Rinaldi L, Monaco L, Ricozzi C, Imbriani S, Nevola R, Adinolfi LE, Sasso FC. Metformin lactic acidosis: Should we still be afraid? Diabetes Res Clin Pract 2019;157:107879. [PMID: 31618624 DOI: 10.1016/j.diabres.2019.107879] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
214 Chen ZD, Chen Q, Zhu YT, Zhang YF, Zhan Y, Chen XF, Liang X, Jia JY, Yu C, Liu HY, Zou JJ, Liu YM, Zhong DF. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers. Clin Ther 2021:S0149-2918(21)00252-6. [PMID: 34366153 DOI: 10.1016/j.clinthera.2021.07.008] [Reference Citation Analysis]
215 Anker MS, von Haehling S, Papp Z, Anker SD. ESC Heart Failure receives its first impact factor. Eur J Heart Fail 2019;21:1490-e8. [PMID: 31883221 DOI: 10.1002/ejhf.1665] [Reference Citation Analysis]
216 Paolillo S, Marsico F, Prastaro M, Renga F, Esposito L, De Martino F, Di Napoli P, Esposito I, Ambrosio A, Ianniruberto M, Mennella R, Paolillo R, Gargiulo P. Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications. Heart Fail Clin 2019;15:341-7. [PMID: 31079692 DOI: 10.1016/j.hfc.2019.02.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
217 Morimoto A, Kadoya M, Kakutani-Hatayama M, Kosaka-Hamamoto K, Miyoshi A, Shoji T, Goda A, Asakura M, Koyama H. Subclinical decrease in cardiac autonomic and diastolic function in patients with metabolic disorders: HSCAA study. Metabol Open 2020;5:100025. [PMID: 32812948 DOI: 10.1016/j.metop.2020.100025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
218 Evangelista I, Nuti R, Picchioni T, Dotta F, Palazzuoli A. Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. Int J Mol Sci 2019;20:E3264. [PMID: 31269778 DOI: 10.3390/ijms20133264] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
219 Fernandes SL, Carvalho RR, Santos LG, Sá FM, Ruivo C, Mendes SL, Martins H, Morais JA. Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. Arq Bras Cardiol 2020;114:120-9. [PMID: 31751442 DOI: 10.36660/abc.20190111] [Reference Citation Analysis]
220 Seferović PM, Jhund PS. Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control. Eur Heart J Suppl 2019;21:M20-4. [PMID: 31908611 DOI: 10.1093/eurheartj/suz219] [Reference Citation Analysis]
221 Lorenzo-almorós A, Cepeda-rodrigo J, Lorenzo Ó. Diabetic cardiomyopathy. Revista Clínica Española (English Edition) 2022;222:100-11. [DOI: 10.1016/j.rceng.2019.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract 2020;159:107946. [PMID: 31778746 DOI: 10.1016/j.diabres.2019.107946] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
223 Fourny N, Beauloye C, Bernard M, Horman S, Desrois M, Bertrand L. Sex Differences of the Diabetic Heart. Front Physiol 2021;12:661297. [PMID: 34122133 DOI: 10.3389/fphys.2021.661297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Cohen CD, De Blasio MJ, Lee MKS, Farrugia GE, Prakoso D, Krstevski C, Deo M, Donner DG, Kiriazis H, Flynn MC, Gaynor TL, Murphy AJ, Drummond GR, Pinto AR, Ritchie RH. Diastolic dysfunction in a pre-clinical model of diabetes is associated with changes in the cardiac non-myocyte cellular composition. Cardiovasc Diabetol 2021;20:116. [PMID: 34074290 DOI: 10.1186/s12933-021-01303-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovasc Diabetol 2021;20:12. [PMID: 33413428 DOI: 10.1186/s12933-020-01205-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
226 Jamalizadeh M, Hasanzad M, Sarhangi N, Sharifi F, Nasli-Esfahani E, Larijani B. Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients. J Diabetes Metab Disord 2021;20:1407-13. [PMID: 34900792 DOI: 10.1007/s40200-021-00874-4] [Reference Citation Analysis]
227 Glover S, Borrego ME, Ray GM, Roberts MH. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit Analysis. Clinicoecon Outcomes Res 2022;14:465-77. [PMID: 35845354 DOI: 10.2147/CEOR.S361886] [Reference Citation Analysis]
228 Cannistraci R, Mazzetti S, Mortara A, Perseghin G, Ciardullo S. Risk stratification tools for heart failure in the diabetes clinic. Nutrition, Metabolism and Cardiovascular Diseases 2020;30:1070-9. [DOI: 10.1016/j.numecd.2020.03.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
229 Silva-Cardoso J, Sheikh O, Nashawi M, Pham S, Gallegos KM, Dinkha LR, Chilton RJ. Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials. J Diabetes 2020;12:279-93. [PMID: 31688975 DOI: 10.1111/1753-0407.13007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
230 Pavlović A, Polovina M, Ristić A, Seferović JP, Veljić I, Simeunović D, Milinković I, Krljanac G, Ašanin M, Oštrić-pavlović I, Seferović PM. Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. Eur J Prev Cardiolog 2019;26:72-82. [DOI: 10.1177/2047487318807767] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
231 Liu A, Li M, Wang J, Feng F, Zhang Y, Qiu Z, Chen Y, Meteku BE, Wen C, Yan Z, Zeng J. Ag@Au core/shell triangular nanoplates with dual enzyme-like properties for the colorimetric sensing of glucose. Chinese Chemical Letters 2020;31:1133-6. [DOI: 10.1016/j.cclet.2019.10.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 9.5] [Reference Citation Analysis]
232 Lawson CA, Zaccardi F, McCann GP, Davies MJ, Kadam UT, Khunti K. Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. JAMA Netw Open 2019;2:e1916447. [PMID: 31790564 DOI: 10.1001/jamanetworkopen.2019.16447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Papp Z, Radovits T, Paulus WJ, Hamdani N, Seferović PM. Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus. Eur J Heart Fail 2018;20:1649-52. [PMID: 30280460 DOI: 10.1002/ejhf.1318] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
234 Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;. [PMID: 33277825 DOI: 10.1002/ehf2.13124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
235 Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Adv Ther 2022;39:845-61. [PMID: 34881413 DOI: 10.1007/s12325-021-01989-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, Okumura T, Kanzaki Y, Onishi K, Kiyosue A, Nishino M, Sakata Y, Node K; CANDLE trial investigators. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. Cardiovasc Diabetol 2021;20:175. [PMID: 34479543 DOI: 10.1186/s12933-021-01369-5] [Reference Citation Analysis]
237 Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJ, Rosano GM. Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:1495-503. [DOI: 10.1002/ejhf.1954] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 18.5] [Reference Citation Analysis]
238 Itier R, Guillaume M, Ricci JE, Roubille F, Delarche N, Picard F, Galinier M, Roncalli J. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. ESC Heart Fail 2021;8:789-98. [PMID: 33534958 DOI: 10.1002/ehf2.13222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
239 Scheen AJ. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view. Diabetes Res Clin Pract 2020;159:107726. [PMID: 31108136 DOI: 10.1016/j.diabres.2019.05.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
240 Delgado E, Jódar E, Mezquita-Raya P, Moreno-Pérez Ó. Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review. Diabetes Ther 2022;13:19-34. [PMID: 35704165 DOI: 10.1007/s13300-022-01278-0] [Reference Citation Analysis]